A Single-Centre Canadian Cost Analysis for the Care and Management of Injection Drug Use-Associated Infective Endocarditis Requiring Cardiac Surgery

加拿大单中心注射吸毒相关感染性心内膜炎(需行心脏手术)的治疗和管理成本分析

阅读:4

Abstract

BACKGROUND: No Canadian data are available on the economic impact of cardiac surgery hospitalizations for injection drug use-related infective endocarditis (IDU-IE) during the current opioid crisis. This study aimed to quantify the healthcare system cost of care for patients with IDU-IE who required cardiac surgery in Calgary, Alberta, Canada. METHODS: A retrospective cohort analysis of the cost of care for patients diagnosed with IDU-IE who had cardiac surgery between 2013 and 2019 was performed. The overall and categorical costs to the Canadian healthcare system for this specific population were quantified using the Alberta Health Services patient coding system and the Alberta Financial General Ledger. RESULTS: Eighteen patients were diagnosed with IDU-IE and had cardiac surgery. The majority of patients underwent isolated tricuspid valve surgery. The mean postoperative intensive care unit and total hospital stays were 5.2 days and 24.9 days, respectively. No 30-day or in-hospital mortalities occurred. The average cost per patient from diagnosis to discharge was CAD$131,072 ± $17,844. The average cost of surgical intervention and postoperative course was CAD$63,090 ± $7983. The highest cost contributor was the cost of in-hospital nursing care. CONCLUSIONS: Patients diagnosed with IDU-IE who have cardiac surgery have higher per-patient cost than the general cardiac surgery population, as shown by comparison to other available data. This specific patient population has unique care needs that should be optimized to improve patient outcomes and improve healthcare resource utilization.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。